Pure Global AI
NCT06391723Not yet recruiting

Clinical, Cognitive and Neural Effects of Potentiation of ECT by rTMS in Treatment-Resistant Depression

Clinical, Cognitive and Neural Effect of Potentiation of Electroconvulsive Therapy (ECT) by Repetitive Transcranial Magnetic Stimulation (rTMS) at 10 ECT in Patients With Characterized Pharmacoresistant Depressive Episode
Centre Hospitalier du RouvrayClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Major Depressive Disorder
Drug/Device/Intervention
Active rTMS
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Centre Hospitalier du Rouvray
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2024
End date
Sep 01, 2026
Enrollment
80 participants
Primary outcome

Response rate after 10 ECT

Summary

Electroconvulsive therapy (ECT) is one of the most effective treatments for
 treatment-resistant depression (TRD). However, due to response delay and cognitive
 impairment, ECT remains an imperfect treatment. In this multicenter, randomized,
 double-blind, sham-controlled study, our objective is to assess the priming effect of rTMS
 sessions before ECT on clinical, cognitive and neural response in patients with TRD.

ICD-10 classifications
Recurrent depressive disorderRecurrent depressive disorder, unspecifiedDepressive conduct disorderOther recurrent depressive disordersRecurrent depressive disorder, current episode moderate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06391723
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06391723 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre Hospitalier du Rouvray and is currently Not yet recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.